Great West Life Assurance Co. Can purchased a new stake in shares of Envista Holdings Co. (NYSE:NVST – Get Rating) during the 3rd quarter, HoldingsChannel.com reports. The institutional investor purchased 108,764 shares of the company’s stock, valued at approximately $3,566,000.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in NVST. Raymond James & Associates grew its stake in shares of Envista by 6.1% in the first quarter. Raymond James & Associates now owns 56,493 shares of the company’s stock worth $2,752,000 after acquiring an additional 3,235 shares during the last quarter. Bank of Montreal Can grew its stake in shares of Envista by 13.9% in the first quarter. Bank of Montreal Can now owns 124,799 shares of the company’s stock worth $6,103,000 after acquiring an additional 15,228 shares during the last quarter. Panagora Asset Management Inc. grew its stake in shares of Envista by 8.1% in the first quarter. Panagora Asset Management Inc. now owns 6,543 shares of the company’s stock worth $319,000 after acquiring an additional 490 shares during the last quarter. Vontobel Holding Ltd. acquired a new stake in shares of Envista in the first quarter worth $390,000. Finally, Vanguard Group Inc. grew its stake in shares of Envista by 1.0% in the first quarter. Vanguard Group Inc. now owns 15,101,226 shares of the company’s stock worth $735,581,000 after acquiring an additional 148,409 shares during the last quarter.
Analyst Upgrades and Downgrades
Several equities research analysts have recently issued reports on NVST shares. Morgan Stanley lowered their price objective on shares of Envista from $49.00 to $48.00 and set an “overweight” rating on the stock in a research note on Thursday, October 13th. William Blair restated an “outperform” rating on shares of Envista in a research note on Thursday, November 3rd. Finally, Piper Sandler decreased their price target on shares of Envista from $46.00 to $44.00 and set an “overweight” rating on the stock in a research note on Friday, November 4th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, Envista currently has an average rating of “Moderate Buy” and a consensus price target of $46.17.
Envista Stock Up 1.2 %
Envista (NYSE:NVST – Get Rating) last issued its quarterly earnings data on Thursday, November 3rd. The company reported $0.47 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.47. The company had revenue of $631.10 million during the quarter, compared to analysts’ expectations of $631.94 million. Envista had a return on equity of 8.33% and a net margin of 9.98%. On average, analysts anticipate that Envista Holdings Co. will post 1.91 EPS for the current year.
Envista Holdings Corporation, together with its subsidiaries, engages in the development, sale, and marketing of dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists, and periodontists under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, and Orascoptic brands; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products under the Damon, Insignia, AOA, and Spark brands.
- Get a free copy of the StockNews.com research report on Envista (NVST)
- Is the Northrop Grumman Selloff an Opportunity?
- Is the Worst Behind for Under Armor Stock with a New CEO?
- What Does Microsoft’s Investment in ChatGBT Mean for MSFT Stock?
- Analysts Like The Fit Of Skechers USA
- Can We Trust The Rally In The S&P 500
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.